CGTX Aligns Pivotal Study
Cognition Therapeutics aligns on key aspects of pivotal study for Zervimesine in DLB psychosis after receiving FDA meeting minutes
CGTX - Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes